Shardul Amarchand Mangaldas & Co (SAM) and JSA are advising Veeda Clinical Research Limited on its proposed IPO, comprising a ₹185 crore fresh issue and an offer for sale of up to 13,008,128 equity shares by existing shareholders.
SAM is acting for Veeda Clinical Research according to the Draft Red Herring Prospectus (DRHP)
JSA is advising Book Running Lead Managers - Axis Capital Limited, IIFL Capital Services Limited, CLSA India Private Limited and SBI Capital Markets Limited.
The transaction team consisted of Madhurima Mukherjee Saha (Lead Partner), Sagar Batra (Principal Associate), Bhavini Mohan (Associate), Nidhi Prakriti (Associate), Aryaman Singh (Associate) and Shashwat Sharma (Associate).
Veeda Clinical Research has refiled its draft red herring prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) for an initial public offering (IPO). The
The IPO comprises a fresh issue of shares worth ₹185 crore and an offer-for-sale of up to 13 million equity shares. The offer-for-sale includes shares from several investors, including Basil Private Limited, Bondway Investments Inc., and Dr. S N Vinaya Babu. The funds raised from the fresh issue will be utilized for capital expenditures, supporting organic growth through marketing and technology upgrades, and general corporate purposes.
Veeda Clinical Research, established in 2004, is a full-service contract research organization (CRO) that provides a comprehensive suite of services across the drug development and launch value chain. These services encompass early and late-phase clinical trials, Healthy Volunteer Studies (HVS), pre-clinical trials, non-clinical testing, and biopharma services.
Veeda specializes in bioavailability and bioequivalence studies, as well as clinical bioanalysis for large molecules.
If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.